The estimated Net Worth of Bryan Stuart is at least $1.48 Миллион dollars as of 10 August 2021. Mr. Stuart owns over 60,000 units of Fulcrum Therapeutics Inc stock worth over $247,800 and over the last 5 years he sold FULC stock worth over $0. In addition, he makes $1,234,960 as Chief Operating Officer at Fulcrum Therapeutics Inc.
Bryan has made over 1 trades of the Fulcrum Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of FULC stock worth $470,400 on 10 August 2021.
The largest trade he's ever made was exercising 60,000 units of Fulcrum Therapeutics Inc stock on 10 August 2021 worth over $470,400. On average, Bryan trades about 10,000 units every 0 days since 2019. As of 10 August 2021 he still owns at least 28,000 units of Fulcrum Therapeutics Inc stock.
You can see the complete history of Mr. Stuart stock trades at the bottom of the page.
Bryan Stuart serves as Chief Operating Officer of the Company. Bryan Stuart serves as Chief Operating Officer of the Company. Bryan Stuart serves as Chief Operating Officer of the Company. Mr. Stuart previously served as president and chief executive officer of Yarra Therapeutics, LLC, or Yarra, a subsidiary of Array Biopharma, Inc., a biopharmaceutical company focused on genetically defined rare diseases, from December 2017 to August 2018. Prior to joining Yarra, Mr. Stuart served as president of Kastle Therapeutics, LLC, or Kastle, a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, from July 2015 to March 2017 and as president and chief executive officer from March 2017 to November 2017. Prior to joining Kastle, Mr. Stuart was the chief business officer of Civitas Therapeutics, Inc., a biopharmaceutical company, from August 2012 to October 2014, where he led the business development, capital raising, commercial and portfolio management functions, including the sale of Civitas to Acorda Therapeutics, Inc. He previously led business development, corporate development and strategy at both EKR Therapeutics Inc. (acquired by Chiesi Farmaceutici S.p.A.) and Ovation Pharmaceuticals Inc. (acquired by Lundbeck A/S), where he played key roles in each company's growth and ultimate sale. Mr. Stuart began his career as a healthcare investment banker at William Blair & Company. Mr. Stuart received an MBA from the Kellogg School of Management at Northwestern University and a B.S. from the University of Illinois.
As the Chief Operating Officer of Fulcrum Therapeutics Inc, the total compensation of Bryan Stuart at Fulcrum Therapeutics Inc is $1,234,960. There are 2 executives at Fulcrum Therapeutics Inc getting paid more, with Robert Gould having the highest compensation of $3,889,350.
Bryan Stuart is 43, he's been the Chief Operating Officer of Fulcrum Therapeutics Inc since 2018. There are 13 older and 1 younger executives at Fulcrum Therapeutics Inc. The oldest executive at Fulcrum Therapeutics Inc is Mark J. Levin, 71, who is the Exec. Chairman.
Bryan's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk и Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include: